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Abstract 
Glycolysis has long been considered as the major metabolic process for energy production and anabolic 
growth in cancer cells. Although such a view has been instrumental for the development of powerful 
imaging tools that are still used in the clinic, it is now clear that mitochondria play a key role in 
oncogenesis. Besides exerting central bioenergetic functions, mitochondria provide indeed building 
blocks for tumor anabolism, control redox and calcium homeostasis, participate in transcriptional 
regulation, and govern cell death. Thus, mitochondria constitute promising targets for the development 
of novel anticancer agents. However, tumors arise, progress and respond to therapy in the context of an 
intimate crosstalk with the host immune system, and many immunological functions rely on intact 
mitochondrial metabolism. Here, we review the cancer cell-intrinsic and -extrinsic mechanisms through 
which mitochondria influence all steps of oncogenesis, with a focus on the therapeutic potential of 
targeting mitochondrial metabolism for cancer therapy. 
  
Introduction 
With the advent of the 21st century, two major misconceptions about cancer have eventually been 
eradicated: (1) the notion that cancer is a purely cell-intrinsic disorder that stems from epigenetic or 
genetic alterations [1, 2]; and (2) the view that malignant cells satisfy their bioenergetic and anabolic 
needs mostly (if not only) via aerobic glycolysis [3, 4]. Thus, it is now widely accepted that tumors 
form, develop and respond to therapy in the context of a complex, bidirectional interaction with the 
host immune system [5, 6]. Similarly, the fundamental influence of mitochondrial metabolism on all 
steps of oncogenesis, i.e., malignant transformation, tumor progression and response to treatment, has 
eventually been given proper recognition [7, 8].  
Interestingly, the roots of these long-standing misconceptions reside in two notions that de facto 
revolutionized (in the positive sense of the term) modern medicine: (1) the “self/non-self” dichotomy, 
as originally theorized by the Australian virologist Sir Frank Macfarlane Burnet (1899-1985) in 1949, 
proposing that the immune system can only recognize foreign entities [9, 10]; and (2) the so-called 
“Warburg effect”, referring to the elevated uptake of glucose that characterizes a majority of cancers, 
first described by the German physiologist Otto Heinrich Warburg (1883-1970) in 1927 [11, 12]. The 
self/non-self theory generated a robust theoretical framework that turned out to be essential for our 
current understanding of immune responses against invading pathogens [9], while the Warburg effect 
provided the rationale for the development of an imaging tool that has been (and still is) extensively 
used in the clinics for the detection and monitoring of neoplasms, 2-[18F]fluoro-2-deoxy-D-glucose 
(18F-FDG) positron emission tomography (PET) [11].  
Despite limited experimental support [12, 13], Warburg himself suggested that the ability of malignant 
cells to maintain elevated glycolytic rates in spite of normal oxygen tension would derive from primary 
mitochondrial defects [14], an incorrect assumption that de facto relegated mitochondria to a role of 
mere bystanders of the oncogenic process for decades. Renovated interest on the role of mitochondria 
in cancer came in the mid-1990s with the demonstration that mitochondrial outer membrane 
permeabilization (MOMP) constitutes a decisive step in the execution of regulated cell death (RCD) 
[15-18]. This discovery drove an intense wave of investigation that - only a few years later – 
culminated with the recognition that most (if not all) cancer cells display an accrued resistance to RCD 
often owing to alterations in the mitochondrial control of the process [19]. As a consequence, 
considerable efforts were focused on the development of molecules that would target mitochondria as a 
strategy for chemo- or radiosensitization [20], and some of these agents are nowadays used in the 
clinics (e.g., venatoclax, which is currently approved for use in patients with chronic lymphocytic 
leukemia) [21]. Alongside, mitochondria attracted renovated attention also from a metabolic 
perspective, in particular as it became clear that: (1) some mitochondrial metabolites are sufficient to 
drive oncogenesis [22], and (2) some mitochondrial circuitries can adapt to serve bioenergetic or 
anabolic functions, hence endowing malignant cells with considerable metabolic plasticity [23, 24]. 
Thus, mitochondrial metabolism now stands out as a promising target for the development of novel 
antineoplastic agents, and several venues are currently being explored in this sense [25, 26]. 
One of the main problems with targeting mitochondria as a strategy to kill malignant cells or sensitize 
them to treatment is that multiple immune effector cells, and in particular CD8+ cytotoxic T 
lymphocytes (CTLs, which are involved in the efficacy of many – if not all – therapies), display 
remarkable metabolic similarities to cancer cells [26, 27]. This calls for the development of refined 
therapeutic approaches whereby malignant cells are selectively targeted while immune cells are spared 
from (or rendered insensitive to) the detrimental effects of treatment. Here, we critically review the 
cancer cell-intrinsic and -extrinsic mechanisms whereby mitochondria influence malignant 
transformation, tumor progression and response to treatment, as we discuss the potential of targeting 
mitochondrial metabolism for cancer therapy.  
Mitochondrial metabolism in malignant transformation 
The term “malignant transformation” generally refers to the conversion of a normal cell into a 
neoplastic precursor that – in the context of failing immunosurveillance – acquires additional 
alterations enabling unrestricted proliferative potential, dissemination and formation of distant 
macrometastases (cumulatively referred to as “tumor progression”) [28]. Importantly, only carcinogen- 
and transgene-driven models of oncogenesis can recapitulate (albeit with several limitations) malignant 
transformation. Conversely, widely employed transplantable models including transformed cells of 
human or rodent origin de facto recapitulate late tumor progression only (as they were derived from 
primary or metastatic lesions that evaded immunosurveillance) [29]. Mitochondria may contribute to 
malignant transformation by at least three major mechanisms: (1) mitochondrial reactive oxygen 
species (ROS) favor the accumulation of potentially oncogenic DNA defects and the activation of 
potentially oncogenic signaling pathways [30]; (2) the abnormal accumulation of specific 
mitochondrial metabolites, including fumarate, succinate and 2-hydroxyglutarate (2-HG), has 
prominent transforming effects (at least in some models) [31]; (3) functional deficits in MOMP or 
mitochondrial permeability transition (MPT) are generally required for the survival of neo-formed 
malignant precursors, which would otherwise succumb to RCD [32, 33].  
ROS are established genotoxins [30], and their requirement for malignant transformation is well 
exemplified by the fact that Trp53-/- mice maintained in relatively hypoxic conditions (10% O2) exhibit 
a considerable survival advantage secondary to markedly reduced level of tumorigenesis as compared 
to Trp53-/- mice maintained in standard atmospheric conditions (21% O2) [34]. Along similar lines, 
hypoxia inhibits spontaneous intestinal carcinogenesis in ApcMin/+ mice as well as carcinogen-driven 
oncogenesis in wild-type BALB/c mice [34]. Moreover, mitochondrial DNA (mtDNA) mutations that 
mildly (but not severely) affect various components of the electron transport chain (ETC) as they 
promote ROS generation have been documented in a variety of tumors [8, 35]. One of the major 
mechanisms that control mitochondrial fitness (and hence limits ROS production) is the autophagic 
removal of damaged mitochondria (commonly known as mitophagy) [36]. In line with this notion, the 
knockdown or knockout of genes that are essential for autophagy (such as Atg5 or Atg7) can promote 
oncogenesis in specific contexts [37-39]. Moreover, Fanconi anemia (FA) genes – which are mutated 
or silenced in a large proportion of human tumors – have recently been involved in mitophagy [40], 
suggesting that (at least part of) the oncosuppressive activity of FA proteins may stem from the 
proficient removal of damaged, mitochondria overproducing ROS. Besides favoring mutagenesis, ROS 
trigger potentially oncogenic signal transduction cascades including mitogen-activated protein kinase 
(MAPK) [28] and epidermal growth factor receptor (EGFR) signaling [41]. 
Succinate dehydrogenase complex iron sulfur subunit B (SDHB), fumarate hydratase (FH), isocitrate 
dehydrogenase (NADP(+)) 1, cytosolic (IDH1), and isocitrate dehydrogenase (NADP(+)) 2, 
mitochondrial (IDH2) are affected by germline or somatic mutations in a variety of human tumors [31]. 
While SDHB and FH are generally hit by loss-of-function mutations, accompanied by the accumulation 
of fumarate and/or succinate, IDH1 and IDH2 frequently display gain-of-function mutations, leading to 
the synthesis of 2-HG [42]. Fumarate, succinate and 2-HG behave as bona fide oncometabolites, 
meaning that their accumulation is sufficient to drive malignant transformation (at least in some 
models) [42]. All these oncometabolites share the capacity to inhibit α-ketoglutarate (α-KG)-dependent 
enzymes that control gene expression at the epigenetic level, such as Jumonji domain (JMJ) histone 
lysine demethylases as well as ten-eleven translocation (TET) dioxygenases [43, 44], resulting in the 
expression of a potentially oncogenic transcriptional program associated with a block in terminal 
differentiation [42, 45, 46]. Moreover, 2-HG alters the α-KG-dependent prolyl oxidase activity of egl-9 
family hypoxia inducible factor 1 (EGLN1, best known as PHD2) and EGLN2 (best known as PHD1), 
hence promoting transformation via a mechanism related to hypoxia inducible factor 1 alpha subunit 
(HIF1A) stabilization or destabilization [44, 47]. Finally, fumarate can also induce a non-enzymatic 
post-translational protein modification known as “succination”, and succination of kelch like ECH 
associated protein 1 (KEAP1) activates the oncogenic transcription factor nuclear factor, erythroid 
derived 2 (NFE2, best known as NRF2) [48]. Interestingly, the accumulation of succinate and fumarate 
does not always result from primary mitochondrial defects, but can also derive from signals dispatched 
from oncogenic proteins such as KRAS [49, 50]. Along similar lines, loss of oncosuppressor genes 
such as APC appears to favor malignant transformation also by altering mitochondrial functions [51]. 
Alterations in the susceptibility of mitochondrial to undergo MOMP or MPT accompany a vast 
majority of human tumors and are required for malignant precursors to undergo oncogene-driven RCD 
[32, 33]. Perhaps the most striking example of such alterations derives from the overexpression of 
BCL2, apoptosis regulator (BCL2), a multifunctional cytoprotective protein that localizes to the 
mitochondrial outer membrane [32]. Malignant transformation (as well as tumor progression, see 
below) in the hematopoietic system is often associated with the overexpression of BCL2 or other 
members of the BCL2 protein family, and this increases considerably the resistance of malignant 
precursors (as well as established cancer cells) to RCD, at least in part owing to an improved 
bioenergetic metabolism [52, 53]. In a subset of follicular lymphoma patients, a chromosomal 
rearrangement involving BCL2 (normally on chromosome 18) and the immunoglobulin heavy chain 
locus (normally on chromosome 14) – the so-called t(14;18) translocation [54] – can be detected in a 
vast majority of blasts, suggesting that it constitutes a very early event in oncogenesis. Many 
oncogenes beyond BCL2 (e.g., MYC, KRAS) drive malignant transformation as they increase the 
resistance of the mitochondrial pool to MOMP or MPT, in some cases via a mechanism that alters 
mitochondrial dynamics [55-57]. Besides triggering RCD, oncogene activation can also promote a 
permanent proliferative arrest known as cellular senescence, generally as a result of increased oxidative 
stress [58]. Cancer cells can evade such a response as they activate pyruvate dehydrogenase kinase 1 
(PDK1) or inhibit pyruvate dehydrogenase phosphatase catalytic subunit 2 (PDP2), resulting in limited 
pyruvate utilization by mitochondria and reduced ROS production [59]. 
Altogether, these observations exemplify the critical influence of mitochondria on malignant 
transformation (Figure 1). 
  
Mitochondrial metabolism in tumor progression  
Mitochondria are key for virtually all facets of tumor progression, not only as a major source of ATP, 
but also due to (1) their ability to provide building blocks for anabolism via anaplerosis, (2) their 
capacity to produce ROS, and (3) their central position in RCD signaling. In line with this notion, the 
ability of mtDNA-depleted (ρ0) cells to form tumors upon inoculation in immunocompatible hosts is 
compromised [60-62], but can be recovered (at least in some settings) upon horizontal transfer of whole 
mitochondria from the host [60, 63]. Along similar lines, severe defects in autophagy or mitophagy – 
resulting in fully compromised mitochondrial functions – have been associated with decreased tumor 
progression in multiple models of oncogenesis [39, 64-66]. 
 
Proliferation. Although in vitro, under optimal growth conditions (which differ significantly from those 
encountered in the tumor microenvironment in vivo), cancer cells can obtain sufficient ATP from 
glycolysis, mitochondria are required for proliferation unless supraphysiological amounts of uridine 
and pyruvate are exogenously provided [67] to compensate for pyrimidine and aspartate biosynthesis 
[68, 69]. Progressing tumors display indeed an extensive and highly plastic metabolic rewiring. This 
involves not only increased uptake of glucose (a fraction of which is redirected to the pentose 
phosphate pathway (PPP) for nucleic acid synthesis and glutathione reduction) [70], but also the ability 
to process glutamine oxidatively (for energy production via the Krebs cycle and the ETC) or 
reductively (for fatty acid synthesis, cholesterol synthesis and the maintenance of oxidative 
homeostasis via NADPH production) [71-74], the ability to flexibly use various other carbon sources 
including (but perhaps not limited to) acetate, lactate, serine and glycine as needed [75-79], and the 
ability to interchangeably use glycolysis, oxidative phosphorylation and fatty acid oxidation as source 
of energy in response to fluctuating microenvironmental conditions (such as local acidosis, which 
inhibits glycolysis) [80]. 
The reversibility of many reactions of the tricarboxylic acid (TCA) cycle and the existence of multiple 
anaplerotic circuitries centered on mitochondria ensure such a metabolic adaptation [25, 81]. One key 
TCA intermediate in this respect is citrate, because it resides at a crucial intersection between catabolic 
and anabolic metabolism, and hence operates as a major node of flexibility [82]. Besides fueling the 
oxidative mode of the TCA, citrate can also be converted into acetyl-CoA for export to the cytoplasm 
and nucleus [4, 81], where it can either be employed for fatty acid and cholesterol synthesis (to support 
the membrane need associated with intense proliferation) or used for acetylation reactions, which 
regulate transcription as well as cytoplasmic processes including autophagy [36, 83, 84]. In line with 
this notion, the enzyme that converts citrate into acetyl-CoA, i.e., ATP citrate lyase (ACLY), is 
required for cancer cells to proliferate at optimal rates [85], but not for normal cells to do so (owing to 
a glucose-to-acetate metabolic switch) [86]. Reductive glutamine metabolism is the major source of 
citrate in the presence of mitochondrial defects, as well as under hypoxic conditions (as a function of 
the α-KG/citrate ratio) [23, 73, 87]. In this latter scenario, serine catabolism via serine 
hydroxymethyltransferase 2 (SHMT2) provides reducing equivalents to sustain NAPDH production 
(which is critical for lipid synthesis and the preservation of redox homeostasis) [79, 88]. Cytosolic 
malic enzyme 1 (ME1) mediates a similar function in pancreatic duct adenocarcinomas (PDACs) and 
highly proliferating breast cancers, ensuring the synthesis of NADPH from glutamate [72, 89]. 
Interestingly, mitochondrial ME2 is deleted in a fraction of human PDACs, which renders them 
dependent on ME3-driven NADPH synthesis for survival and proliferation [90]. 
Acetyl-CoA-derived acetoacetate also supports cancer proliferation by boosting BRAF kinase activity 
and consequence MAPK signaling [91, 92]. Along similar lines, slightly elevated levels of ROS 
stimulate proliferation by inactivating tumor suppressors such as phosphatase and tensin homolog 
(PTEN) or by stabilizing HIF1A [93, 94]. Moreover, physiological ROS levels contribute to the 
regulation of mitochondrial dynamics [95], which is intimately involved not only in mitochondrial 
biogenesis, but also in the control of mitochondrial metabolism [96]. In line with this notion, multiple 
tumors overexpress ATPase inhibitory factor 1 (ATPIF1), which favors the dimerization of ETC 
complex V to boost ATP production and (as a side effect) increases ROS generation [97, 98]. 
Intriguingly, ROS-driven cellular senescence can paradoxically support proliferation in a cell-extrinsic 
manner, as it sustains the secretion of mitogenic factors that act on neighboring cancer cells with intact 
proliferative capacities [99, 100]. These observations exemplify the fundamental role of mitochondrial 
products at the interface of metabolism and signaling. 
 
Resistance to spontaneous RCD. Progressing neoplasms encounter harsh microenvironmental 
conditions (e.g., hypoxia, low nutrient availability, growth factor withdrawal), which would normally 
drive mitochondrial RCD via MOMP or MPT [32, 33]. Malignant cells, however, acquire several 
alterations that increase the mitochondrial threshold for irreversible permeabilization, beyond the 
overexpression of BCL2 family members (see above) [101]. Some (but not all) tumors are 
characterized by an elevated mitochondrial transmembrane potential (Δψm) linked to high glycolytic 
rates and increased resistance to RCD [102]. In this scenario, restoring pyruvate generation with 
chemical PDK1 inhibitors appears to be sufficient to cause RCD and inhibit tumor growth in vivo 
[102]. Similarly, detaching hexokinase 1 (HXK1) or HXK2 – the enzymes that convert glucose into 
glucose-6-phosphate in the first step of glycolysis – from mitochondria has been proposed to cause 
MOMP in cancer cells of different origin [103]. Moreover, the increased abundance of reduced 
glutathione that originates from a proficient reductive metabolism prevents cytochrome c, somatic 
(CYCS) from oxidation, which limits its capacity to activate apoptotic RCD upon MOMP [104]. The 
maintenance of optimal antioxidant defenses is also fundamental for cancer cells to avoid ROS-driven 
MPT, and oncogene signaling, glycolysis as well as reductive glutamine carboxylation play a major 
role in this sense [88, 105, 106]. Interestingly, such a defense mechanism – which is partially related to 
the Warburg effect – appears to be conserved in yeast [107]. That said, slightly elevated ROS levels 
may increase the resistance of cancer cells to RCD by (1) triggering an adaptative hormetic response 
reminiscent of ischemic preconditioning [108, 109], and/or (2) promoting autophagy activation [110]. 
Interestingly, the supramolecular entity responsible for MPT, the so-called “permeability transition 
pore complex” operates in the context of physical and functional interactions with ETC components 
(notably, complex V) and other constituents of the molecular machinery for mitochondrial ATP 
synthesis [98]. In several cancer cells, proficient ATP production by mitochondria is associated with 
optimal Ca2+ homeostasis and limited MPT sensitivity [111]. Mitochondrial dynamics is also involved 
in the increased resistance of cancer cells to MOMP and MPT. Malignant cells cope with glucose 
deprivation by shifting to oxidative phosphorylation (OXPHOS) upon mitochondrial elongation 
secondary to dynamin 1 like (DNM1L) inhibition [112], which is important to generate an efficient 
mitochondrial network upon the mitophagic removal of dysfunctional components [113]. Taken 
together, these observations suggest the existence of an intimate and bidirectional link between 
metabolism and mitochondrial RCD control. 
 
Diversification and interaction with the stroma. Progressing malignancies acquire a high degree of 
phenotypic and metabolic plasticity as they establish functional interactions with non-transformed 
components of the tumor microenvironment [114-116]. Both these aspects of the biology of malignant 
cells have been largely overlooked by studies based on cultured cancer cell lines. Recent in vivo work 
revealed that not only the oncogenic driver, but also the tumor microenvironment (in particular tissue 
of origin) influence the metabolic profile of malignant cells [117-119].  
One of the (hitherto debated) models of tumor evolution proposes the existence of a cancer stem cell 
(CSC) population endowed with self-renewing ability and responsible for both local progression and 
recurrence [120]. As compared to their more differentiated counterparts, CSCs from multiple 
malignancies including osteosarcoma, glioblastoma and breast cancer display a predominantly 
glycolytic metabolism [121-123]. However, CSCs from other tumors such as ovarian cancer appear to 
primarily rely on OXPHOS for ATP synthesis [124]. Interestingly, different subsets of CSCs from the 
same tumor have been reported to preferentially catabolize glucose in a disparate manner [125, 126], 
suggesting that an additional layer of heterogeneity may exist within the CSC compartment to favor 
metabolic plasticity [127, 128]. That said, the study of CSCs is complicated by the lack of widely 
accepted surface biomarkers for isolation, as well as by the tendency of these cells to rapidly evolve in 
culture. This implies that additional investigation is required to elucidate the precise metabolic profile 
of CSCs from different tumors and whether mitochondrial metabolism may offer targets for therapeutic 
interventions in this setting.  
Prostate cancer cells reprogram tumor-associated fibroblasts (TAFs) towards anaerobic glycolysis, 
resulting in lactate secretion in the microenvironment and lactate-driven oxidative metabolism in 
malignant cells [129]. Along similar lines, PDAC cells drive TAFs into autophagic responses that 
ultimately sustain tumor growth by increasing the local availability of alanine (employed by cancer 
cells as a carbon source) [130]. Extracellular proteins can also be utilized by PDAC cells for carbon 
supply upon macropinocytosis [131], but thus far no mechanisms whereby cancer cells stimulate 
protein secretion by non-transformed components of the tumor microenvironment for nutritional 
purposes have been described. Along similar lines, prostate, ovarian, breast and colorectal cancer cells 
have been shown to obtain fatty acids for oxidative metabolism from local adipocytes, providing a 
support to tumor progression [132-135]. These observations exemplify parasitism-like relationships 
established by malignant cells in the tumor microenvironment. In addition, cancer cells can engage in 
metabolic competition for nutrients at limited availability, such as glucose and tryptophan, with 
immune effector cells (which reflect the metabolic similarities between highly proliferating cells) [136-
138]. Such a competition is expected to influence the likelihood of natural immunosurveillance to 
control tumor progression. Finally, cancer cells from different regions of the tumor have been proposed 
to engage in a metabolic symbiosis involving the transfer of glycolysis-derived lactate from hypoxic to 
normoxic areas, where it would be employed to fuel oxidative phosphorylation (as a strategy to avoid 
competition for glucose) [139, 140]. Additional investigation is required to elucidate the actual 
pathophysiological relevance of this process in human malignancies. 
 
Metastatic dissemination. The term metastatic dissemination (also known as metastatic cascade) 
generally refers to a multi-step process whereby cancer cells acquire the ability to colonize and form 
macroscopic lesions at distant sites [141]. Although macrometastases are generally considered as 
glycolytic entities (because they are often detectable by 18F-FDG PET), this is not always the case 
[142]. One of the first alterations of the metastatic cascade is the so-called epithelial-to-mesenchymal 
transition (EMT), which endows malignant cells with increased invasive potential [143]. Several 
mitochondrial metabolites favor the EMT [144], in particular fumarate (owing to its ability to repress 
the transcription of the antimetastatic microRNAs upon inhibition of TET dioxygenases) [145]. 
Optimal mitochondrial biogenesis and OXPHOS seem also to be required for metastatic dissemination, 
as demonstrated upon silencing of the master regulator PPARG coactivator 1 alpha (PPARGC1A, best 
known as PGC-1α) in models of breast cancer [146], and upon silencing of family with sequence 
similarity 210 member B (FAM210B) in models of ovarian cancer (resulting in PDK4 downregulation 
and consequent utilization of glycolytic pyruvate in the TCA cycle) [147]. Moreover, local invasion 
relies (at least in part) on oxidative mitochondrial metabolism at the cellular leading edge, resulting in 
cytoskeletal alterations required for motility [148-150]. Mitophagic defects also promote metastatic 
dissemination [151], most likely by favoring mild ROS overproduction [152-154]. ROS activate indeed 
several signal transduction cascades associated with metastatic dissemination, including SRC and 
protein tyrosine kinase 2 beta (PTK2B) signaling [153, 155]. In line with this notion, a genetic 
signature of mitochondrial dysfunction has been associated with metastatic dissemination and dismal 
prognosis in patients affected by 9 different tumors [156]. Of note, imbalances in mitochondrial 
dynamics have also been linked with mild ROS overproduction and consequent metastatic 
dissemination [157, 158]. Conversely, in the presence of severe oxidative stress, ROS de facto inhibit 
metastatic dissemination, most likely as a direct consequence of reduced fitness and RCD or cellular 
senescence [159-161]. In summary, although established macrometastases are generally characterized 
by elevated glucose uptake (presumably reflecting an intense glycolytic metabolism that boosts 
antioxidant defenses) [107], OXPHOS and consequent ROS generation (provided it remains below a 
cytotoxic threshold) are required for previous steps of the metastatic cascade. Most likely, there is a 
considerable heterogeneity in the extent to which metastatic lesions of different origin [117] or at 
different anatomical locations [162] actually rely on glycolytic versus respiratory metabolism. Further 
investigation is required to shed light onto all the factors that influence the metabolic profile of 
macrometastatic lesions. 
Altogether, these considerations suggest that mitochondria reside at a preferential hub connecting 
metabolism and signaling that is fundamental for tumor progression (Figure 2). 
  
Mitochondrial metabolism and therapeutic responses  
The ultimate objective of conventional chemotherapeutics, targeted anticancer agents, radiation therapy 
as well as immunotherapy is to elicit the death or permanent inactivation (via cellular senescence or 
terminal differentiation) of malignant cells (directly and/or as a consequence of immunological 
mechanisms) [6]. Mitochondria are critically involved in the control of RCD triggered by all these 
treatments, implying that alterations of the propensity of mitochondria to undergo MOMP or MPT 
underlie a majority of cases of primary and acquired resistance [163-166]. As mentioned above, this 
notion drove an intensive wave of research aimed at the identification of molecules that would kill 
transformed cells or sensitize to treatment by priming MOMP or MPT, such as the FDA-approved 
agent venatoclax [21]. Discussing the regulation of apoptotic and necrotic RCD by mitochondria in 
details goes beyond the scope of the present review [167, 168]. That said, however, it should be noted 
that (1) RCD regulation at mitochondria involves a robust metabolic (rather than purely structural) 
component; (2) several metabolic aspects of the mitochondrial biology also influence therapeutic 
responses [101, 169] and (3) metabolic enzymes residing within mitochondria such as mutant IDH2 are 
being harnessed for the development of anticancer agents promoting terminal differentiation [45, 170, 
171]. 
BRAFV600E inhibition with the FDA-approved vemurafenib is associated with a switch from glycolysis 
to OXPHOS, which is required for melanoma cells to resist treatment [172]. In this model, the ETC 
inhibitor honokiol is sufficient to abrogate resistance and restore cancer cell killing by vemurafenib 
[172]. Oncogene ablation in KRASG12D-driven PDAC cells results in the selection of a subpopulation 
of cells predominantly relying on OXPHOS for energy production [173]. A similar switch from 
glycolysis to OXPHOS has also been documented upon MYC/KRAS or MYC/ERBB2 ablation in 
breast cancer cells [174], and in the context of acquired resistance to phosphoinositide-3-kinase (PI3K) 
inhibition in glioma cells [175]. Moreover, resistance to PI3K inhibition in breast cancer cells has been 
linked to a switch from glucose to lactate as a main source of carbon units [176]. The activity of 
various transporters of the ATP-binding cassette (ABC) family - which support chemoresistance as 
they export a wide spectrum of xenobiotics - depends on OXPHOS-derived ATP availability [177]. In 
some cases, the expression of ABC transporters and the consequent acquisition of a chemoresistant 
phenotype stems from OXPHOS-driven inflammatory reactions culminating in the secretion of 
interleukin 6 (IL6) and tumor necrosis factor (TNF) into the tumor microenvironment [178]. Thus, in 
cells with a predominantly glycolytic metabolism, OXPHOS can promote resistance to treatment via 
both cancer cell-intrinsic and extrinsic pathways. Conversely, malignant cells that predominantly 
utilize OXPHOS for energy production, including pancreatic CSCs, can become resistant to ETC 
inhibition as they acquire a partially glycolytic metabolism depending on MYC expression [179]. 
Likewise, chemoresistant ovarian cancer cells display a switch from OXPHOS to glycolysis 
accompanied by a PPP-dependent surge in antioxidant defenses [180]. Taken together, these 
observations suggest that the ability of most (if not all) cancer cells to flexibly rewire their 
mitochondrial metabolism underlie multiple instances of chemoresistance. This holds true for 
antineoplastic agents other than conventional chemotherapy, including radiation therapy [181] 
antiangiogenic drugs [182-184], and natural killer (NK)-based immunotherapy [185]. In this latter case, 
OXPHOS supports the resistance of cancer cells to NK cell-mediated lysis as it promotes the 
expression of MHC class I molecules (potentially resulting in restored sensitivity to CTL-mediated 
lysis) [185]. 
Thus, different forms of treatment establish compensatory metabolic networks that support cancer cell 
survival. Importantly, such metabolic perturbations may provide targets for the development of novel 
agents that sensitize cancer cells to treatment. Preclinical evidence in support of this notion is 
accumulating [186]. In summary, besides controlling multiple forms of RCD, mitochondria impact the 
response of cancer cells to treatment via metabolic rewiring (Figure 3).  
Mitochondrial metabolism in immunosurveillance 
Mitochondria influence immunosurveillance via both cancer cell-intrinsic and cancer cell-extrinsic 
mechanisms. On the one hand, mitochondria are the source of many danger signals released by cancer 
cells as they die, and these signals are crucial for the activation of dendritic cells to optimally prime 
tumor-targeting immune responses [187]. On the other hand, mitochondrial metabolism is involved in 
many functions linked to anticancer immunity, including (but not limited to) inflammasome activation, 
the establishment of protective immunological memory as well as the differentiation and tumoricidal 
activity of specific macrophage subsets [188, 189].  
The best characterized mitochondrial product that participates in the elicitation of immune responses to 
dying cancer cells is ATP [190]. Extracellular ATP - which dying cancer cells can release in 
considerable amounts only if they can mount autophagic responses before death [191, 192] - mediates 
indeed prominent immunostimulatory and chemotactic functions upon binding to purinergic receptor 
P2X 7 (P2RX7) and purinergic receptor P2Y2 (P2RY2), respectively, on the surface of dendritic cells 
(DCs) or their precursors [193-195]. In line with this notion, autophagy-deficient malignant cells lose 
the ability of driving anticancer immunity as they succumb to chemotherapy or radiation therapy in 
vivo, a detrimental effect that can be partially corrected by inhibiting extracellular ATP degradation by 
ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1; best known as CD39) [191, 196, 197]. 
Moreover, autophagy activation with caloric restriction or molecules that mimic the biochemical 
effects of starvation boosts the therapeutic efficacy of immunogenic treatment modalities (including 
anthracycline-based chemotherapy) in rodent tumor models, an effect that is abolished by the depletion 
of ATG5 or ATG7 as well as by the overexpression of CD39 [196, 198, 199]. Mitochondria contain 
many other molecules that can operate as extracellular danger signals, including (but not limited to) N-
formylated peptides and mtDNA [187]. However, while the relevance of some of these molecules in 
other disease settings (e.g., systemic inflammatory response syndrome) is well established [200], their 
role in anticancer immunity remains to be fully elucidated. Indeed, the receptor for N-formylated 
peptides (which is expressed by DCs) appears to be required for dying cancer cells to elicit a tumor-
targeting immune response, but it does so by binding to another danger signal, i.e., annexin A1 
(ANXA1) [201]. That said, the release of mtDNA upon MOMP promotes the secretion of type I 
interferon (IFN) by malignant cells, and this is required for the activation of optimal anticancer immune 
responses upon chemotherapy and radiation therapy [202-205]. Thus, mtDNA also operates as an 
intracellular danger signal to relay intracellular stress responses to the preservation of extracellular 
homeostasis [206]. 
CTLs and helper T cells responding to antigenic stimulation engage in a proliferative response that – 
similar to cancer cell proliferation – extensively relies on glycolysis and is supported by mitochondrial 
fragmentation [207-209]. In addition, mitochondrial ROS are required not only for proximal TCR 
signaling, but also for the activation of multiple transcription factors necessary for optimal T-cell 
functions, such as NF-kB and nuclear factor of activated T-cells 1 (NFATC1; best known as NFAT) 
[210, 211]. At odds with their effector counterparts, memory T cells predominantly rely on fatty acid 
oxidation and OXPHOS to support their metabolic needs, a result of a metabolic reprogramming that 
involves not only mitochondrial elongation but also mechanistic target of rapamycin complex 1 
(MTORC1) inhibition coupled to autophagy activation [208, 212, 213]. Intriguingly, a similar 
metabolic profile is also displayed by immunosuppressive cell types including CD4+CD25+FOXP3+ 
regulatory T cells and myeloid-derived suppressor cells [214, 215], which presumably renders them 
less sensitive to metabolic competition for glucose within them tumor microenvironment. 
Macrophage polarization and activity are also influenced by mitochondrial metabolism. On the one 
hand, inhibition of the ETC appears to promote the differentiation of macrophages toward a pro-
inflammatory and tumoricidal state (generally referred as to M1), which display a predominantly 
glycolytic metabolism secondary to the autophagic removal of mitochondria [216-218]. Conversely, 
M2-polarized macrophages, which generally exert tumor-supporting functions, preferentially employ 
OXPHOS as a source of ATP, especially in hypoxic conditions [219, 220]. However, the oxidative 
burst that underlies the phagocytic activity of M1 macrophages depends on ROS of direct or indirect 
(via NADPH) mitochondrial derivation [221]. A similar consideration applies to the pro-inflammatory 
activity of M1 macrophages, which relies on ROS-dependent NF-κB transcriptional responses as well 
as on the activation of the so-called inflammasome, a supramolecular platform that synthesizes IL1B 
and IL18 in a ROS- and mtDNA-dependent manner [222, 223]. 
Taken together, these observations exemplify the intricate involvement of mitochondrial metabolism in 
anticancer immunosurveillance (Figure 4).  
Concluding remarks and perspectives 
Mitochondria have attracted considerable attention as targets for the development of novel anticancer 
agents, not only because they have a central role in the resistance of malignant cells to RCD induction 
by treatment, but also because they underlie their phenotypic and metabolic plasticity (Figure 5). The 
case of venatoclax, a molecule that triggers RCD by mimicking the activity of pro-apoptotic members 
of the BCL2 protein family, well exemplifies the high potential of agents targeting mitochondria for the 
treatment of specific malignancies [21]. However, non-specifically targeting mitochondrial functions 
within the tumor microenvironment may have major unwarranted effects including the inhibition of 
anticancer immune responses, a situation that reminisces the use of pharmacological inhibitors of 
autophagy [224]. Thus, refined strategies that allow for specifically modulating mitochondrial 
functions in selected cell populations will have to be devised for the therapeutic potential of 
mitochondria-targeting agents to be fully harnessed in the clinics. A large body of preclinical and 
clinical work is still required for this ambitious objective to become a clinical reality. 
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Legends to Figures 
Figure 1. Mitochondrial metabolism in malignant transformation. Mitochondrial dysfunction can 
promote malignant transformation, i.e., the conversion of a healthy cell into a malignant precursor, as a 
consequence of (1) reactive oxygen species (ROS) overgeneration, which favors mutagenesis; (2) 
accumulation of succinate, fumarate or 2-hydroxyglutarate (all of which can operate as 
oncometabolites, at least in some settings); and/or (3) increased resistance to oncogene-driven 
mitochondrial outer membrane permeabilization (MOMP)- or mitochondrial permeability transition 
(MPT)-driven regulated cell death or cellular senescence.  
Figure 2. Mitochondrial metabolism in tumor progression. Mitochondria influence multiple 
processes that underpin tumor progression, including the proliferation of transformed cells, their 
resistance to adverse microenvironmental conditions, their diversification, their interaction with the 
tumor stroma, and their dissemination towards distant anatomical sites. In particular, (1) mitochondria 
are major sources of ATP and building blocks for the proliferation of malignant cells; (2) progressing 
cancer cells display an increased threshold for mitochondrial outer membrane permeabilization 
(MOMP) and mitochondrial permeability transition (MPT), which renders them less sensitive to harsh 
microenvironmental conditions; (3) slightly supraphysiological levels mitochondrial reactive oxygen 
species (ROS) foster tumor diversification (herein represented with assorted plasma membrane colors) 
by favoring mutagenesis; (4) different subsets of malignant cells exhibit differential metabolic profiles, 
which are important for their survival and function; (5) the metastatic cascade relies on optimal 
mitochondrial biogenesis and oxidative phosphorylation (OXPHOS), at least at the initial dissemination 
step. However, imbalanced ROS overproduction consequent to severe mitochondrial dysfunction is 
generally incompatible with tumor progression, resulting in MOMP- or MPT-driven regulated cell 
death or cellular senescence. 
Figure 3. Mitochondrial metabolism in response to treatment. All forms of treatment, including 
chemotherapy, radiation therapy and immunotherapy, aim at triggering the demise – via regulated cell 
death (RCD) – or permanent inactivation – via cellular senescence, of malignant cells (directly, or as a 
consequence of immunological mechanisms). Thus, mitochondria control therapy-driven RCD in 
cancer cells, implying that alterations in the molecular mechanism underpinning mitochondrial outer 
membrane permeabilization (MOMP) and mitochondrial permeability transition (MPT) are a major 
source of resistance. Moreover, mitochondrial ATP fuels several pumps of the ATP-binding cassette 
family, hence fostering chemoresistance upon the extrusion of xenobiotics from malignant cells. 
Finally, the ability of malignant cells to flexibly switch between glycolysis and oxidative 
phosphorylation appears to play a major role in multiple instances of resistance to oncogene inhibition. 
Figure 4. Mitochondrial metabolism in immunosurveillance. Mitochondria are fundamental for the 
recognition of cancer cells by the immune system, as well as for the consequent activation of a tumor-
targeting immune response. On the one hand, mitochondrial products including ATP, reactive oxygen 
species (ROS) and mitochondrial DNA (mtDNA) operate as danger signals, either extracellularly (like 
ATP) or intracellularly (like ROS and mtDNA). On the other hand, mitochondrial ROS are required for 
T-cell activation in response to TCR engagement, and oxidative phosphorylation (OXPHOS) is 
required for the establishment of immunological memory as well as for the tumoricidal and pro-
inflammatory activity of M1 macrophages. However, OXPHOS also supports the differentiation of 
immunosuppressive cells including M2 macrophages (MΦ), CD4+CD25+FOXP3+ regulatory T (TREG) 
cells and myeloid-derived suppressor cells (MDSCs). CTL, cytotoxic T lymphocyte. 
Figure 5. Mitochondrial metabolism and oncogenesis. Mitochondria have a major impact on 
virtually all processes linked to oncogenesis, encompassing malignant transformation, tumor 
progression, response to treatment and anticancer immunosurveillance. C, cancer cell; D, dying cancer 
cell; L, lymphocyte; M, metastatic cancer cell; mtDNA, mitochondrial DNA; MOMP, mitochondrial 
outer membrane permeabilization; MPT, mitochondrial permeability transition; N, normal cell; 
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